Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kraig Biocraft LaboratoriesKBLB ROC (Joel Greenblatt) % is -1,649.87% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 1,605 Chemicals companies, Kraig Biocraft Laboratories ranks worse than 99.56% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Kraig Biocraft Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,649.87%.
The historical rank and industry rank for Kraig Biocraft Laboratories's ROC (Joel Greenblatt) % or its related term are showing as below:
KBLB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4972.88 Med: -1829.6 Max: -819.75
Current: -2098.51
During the past 13 years, Kraig Biocraft Laboratories's highest ROC (Joel Greenblatt) % was -819.75%. The lowest was -4972.88%. And the median was -1829.60%.
KBLB's ROC (Joel Greenblatt) % is ranked worse than 99.56% of 1605
companies
in the Chemicals industry
Industry Median: 9.4
vs KBLB: -2098.51
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KBLB vs AMTX, FSI, NTIC: ROC (Joel Greenblatt) % Comparison
For the Specialty Chemicals subindustry, Kraig Biocraft Laboratories's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kraig Biocraft Laboratories ROC (Joel Greenblatt) % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Kraig Biocraft Laboratories's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Kraig Biocraft Laboratories's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -1,649.87% mean?
Kraig Biocraft Laboratories (KBLB) has a ROC (Joel Greenblatt) % of -1,649.87% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Kraig Biocraft Laboratories and its competitors. According to the industry distribution chart, Kraig Biocraft Laboratories ranks #1598 out of 1605 companies in the Chemicals industry, placing it in the top 99.6%.
Is Kraig Biocraft Laboratories' ROC (Joel Greenblatt) % too high?
Kraig Biocraft Laboratories' current ROC (Joel Greenblatt) % is -1,649.87%. Based on the distribution chart, Kraig Biocraft Laboratories ranks #1598 out of 1605 companies in the Chemicals industry, which is in the bottom quartile relative to peers.
How does Kraig Biocraft Laboratories' ROC (Joel Greenblatt) % compare to AMTX and FSI?
According to the Chemicals industry distribution chart, Kraig Biocraft Laboratories ranks #1598 out of 1605 companies for ROC (Joel Greenblatt) %. This places Kraig Biocraft Laboratories in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 9.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Chemicals company?
The median ROC (Joel Greenblatt) % among Chemicals companies is 9.40, based on 1,605 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Kraig Biocraft Laboratories and its competitors. For the Chemicals industry, the median ROC (Joel Greenblatt) % is 9.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kraig Biocraft Laboratories's current ROC (Joel Greenblatt) % is -1,649.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kraig Biocraft Laboratories stock overvalued right now?
Kraig Biocraft Laboratories (KBLB) has a current ROC (Joel Greenblatt) % of -1,649.87%. The current ROC (Joel Greenblatt) % is -1,649.87%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Kraig Biocraft Laboratories (KBLB), the current ROC (Joel Greenblatt) % is -1,649.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kraig Biocraft Laboratories Inc is engaged in the development of high-strength fiber using recombinant DNA technology mainly for commercial applications. It uses genetic engineering technologies to develop fibers with greater strength, resiliency, and flexibility for use in its target markets, namely the textile, specialty fiber, and technical textile industries. Its products include Monster Silk, which incorporates the natural elasticity of spider silk to make a silk fiber that is more flexible than conventional silk fibers and textiles; Dragon Silk, which combines the elasticity of Monster Silk with additional high-strength elements of native spider silk; Spydasilk; and Spydra.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KBLB has been successfully added to your 
